| Document |
Document Title |
|
WO/2022/195288A1 |
The invention relates to a process for preparing an N-acylethanolamide derivative.
|
|
WO/2022/198139A1 |
The present disclosure relates to compounds of Formula (I): (I) or pharmaceutically acceptable salts thereof. The present disclosure also relates to uses of the compounds, e.g., in treating or preventing diseases, disorders, or condition...
|
|
WO/2022/196860A1 |
The present invention relates to a method for manufacturing a temperature- and stress-sensitive film, and a temperature and stress measurement system and, more specifically, to: manufacturing a flexible temperature- and stress-sensitive ...
|
|
WO/2022/197681A1 |
Disclosed herein are salts of the compound of Formula (I) and polymorphs thereof, methods of making the same, and their methods of use in treating eye diseases and disorders, particularly those associated with inflammation and/or vascula...
|
|
WO/2022/188501A1 |
The present disclosure relates to the technical field of resource reutilization, and provides a recycling method for degraded waste of an acetyl Meldrum's acid derivative. According to the present disclosure, the degraded waste of the ac...
|
|
WO/2022/189190A1 |
The invention relates to compounds of formula (I), and their use as herbicides. In said formula, R1 to R8 represent groups such as hydrogen, halogen or organic groups such as alkyl, alkenyl, alkynyl, or alkoxy; X is a bond or a divalent ...
|
|
WO/2022/188302A1 |
Disclosed are a pregabalin artificial hapten and a pregabalin artificial antigen, preparation methods therefor, and applications thereof. The molecular structural formula of the pregabalin artificial hapten is as shown in formula (I), an...
|
|
WO/2022/183762A1 |
Disclosed are an anti-phenacetin monoclonal antibody hybridoma cell strain AD, and a preparation method therefor and the use thereof, which relate to the technical field of food safety and immunological detection. The deposit name of the...
|
|
WO/2022/183281A1 |
Among other things, in general, compositions and methods of treatment for muscular dystrophy and other diseases are disclosed. A method of treatment of a subject is disclosed, in which fatty acid utilization is improved. The method inclu...
|
|
WO/2022/180638A1 |
The present invention provides additive compound for warm mix asphalt (WMA) for the paving of road surfaces, whereby the additive compounds facilitate the mixing, lay down and compaction of asphalt mixes at low temperatures while retaini...
|
|
WO/2022/178440A1 |
Provided herein are novel compounds of Formula (I): wherein R1 is selected from the group of C1-C20 alkyl, -CH2-CH2-CH2-NH-C(=O)-C=C, and -CH2-CH2-CH2-N(CH3)-C(=O)-C=C; along with compositions comprising them and uses, including as denta...
|
|
WO/2022/169284A1 |
The present invention relates to a novel compound which enables additional hydrogen bonding with amino acids at specific positions of histone acetyltransferase (HAT) p300 through the structural analysis of HAT p300. The novel compound ac...
|
|
WO/2022/157106A1 |
The presently claimed invention relates to a process for the preparation of mono-, di-, tri-, fluoro arylamide or hetroarylamide.
|
|
WO/2022/152705A1 |
Compounds of Formula (I) wherein R1, R3, R11, R12, X, Y1, Y2, Y3, Y4 and formula (II) are as defined in the description. Medicaments.
|
|
WO/2022/152109A2 |
Provided herein are lipid compounds that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nuc...
|
|
WO/2022/149462A1 |
A light-absorbing material according to one embodiment of the present disclosure includes a compound represented by formula (1) as a main component. In formula (1): R1 to R30 are independent of each other and include at least one element...
|
|
WO/2022/150314A1 |
The present disclosure is concerned with substituted phenyl and heterocycloalkyl compounds for the treatment of various cancers such as, for example, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical canc...
|
|
WO/2022/145923A1 |
The present invention relates to a pharmaceutical composition which is for preventing or treating viral infections and contains a piperlongumine-based compound as an active ingredient. Specifically, the piperlongumine-based compound acco...
|
|
WO/2022/145707A1 |
The present invention provides a novel piperlongumine-based compound, and an immunomodulator and a health functional food for immunomodulation, which comprise the compound or a pharmaceutically acceptable salt or solvate thereof as an ac...
|
|
WO/2022/133594A1 |
The present disclosure relates to methods for the hydroaminoalkylation of an olefin. Such methods can comprise reacting the olefin with a secondary amine in the presence of a catalyst of Formula (I). The present disclosure also relates t...
|
|
WO/2022/133544A1 |
Cannabidiol (CBD) cannabinoids and CBD cannabinoid analogues with, inter alia, antimicrobial activity, synthetic methods for the preparation thereof and medical uses and formulations containing same.
|
|
WO/2022/134287A1 |
The present invention relates to a method for preparing a carboxylic acid ester compound. Under the catalysis of nitrite, an carboxylic acid reacts with an alcohol in air so as to obtain an ester compound; and the alcohol is ethanol, pro...
|
|
WO/2022/140654A1 |
The present disclosure relates to compositions and methods related to bicyclo[2.2.1] heptanamine-containing compounds and salts thereof.
|
|
WO/2022/134297A1 |
The present invention relates to a preparation method for a carboxylate ester compound, comprising: under the catalysis of a nitrite ester, reacting carboxylic acid and methanol in air, so as to obtain an ester compound. The preparation ...
|
|
WO/2022/132455A1 |
A composition comprises one or more trimesic acid derivatives of Formula (I) in which R1, R2, and R3 are independently selected from the group consisting of alkyl groups. A polymer composition comprises a composition as described above a...
|
|
WO/2022/133236A1 |
Forms of 2-(4-chlorophenoxy)-N-[3-[5-[cis-3-(trifluoromethoxy)cyclobu
tyl]-1,3,4-oxadiazol-2-yl]-1-bicyclo[1.1.1]pentanyl]acetamid
e, designated herein as Compound I, were prepared and characterized in the solid state. Also provided are ...
|
|
WO/2022/121317A1 |
Disclosed is a 1,1'-biphenyl-2,6-diphenolic compound and the use thereof. The 1,1'-biphenyl-2,6-diphenolic compound is a new compound, and has good biological activity. By means of in vitro tumor cell activity experiments, it was found t...
|
|
WO/2022/120048A1 |
The present disclosure is directed to chromane compounds, chromane compounds demonstrating HDAC inhibition, and pharmaceutical compositions thereof. Additional embodiments include methods of using the chromane compounds. For example, the...
|
|
WO/2022/112347A1 |
The present invention relates to malonamide compounds of the formula (I) wherein the variables are as defined in the claims and the description, and to compositions comprising these compounds. The invention also relates to the use of sai...
|
|
WO/2022/111493A1 |
A use of a complex of an ARB metabolite and an NEP inhibitor in the preparation of drugs for the prevention and/or treatment of nephropathy.
|
|
WO/2022/102557A1 |
The present invention relates to: a compound represented by formula (I) (in the formula, X denotes -CH2- or -NH-; R1 and R3 each independently denote a substituted or unsubstituted hydrocarbon group having 5-30 carbon atoms, with any -CH...
|
|
WO/2022/103838A1 |
The present disclosure relates to methods of screening compounds which reduce or inhibit CHMP7 in neuronal cells or a population of cells and methods of inhibiting CHMP7 expression in a cell to treat one or more subjects suffering from o...
|
|
WO/2022/104137A1 |
The disclosure provides recording materials including propane derivatized monomers and polymers for use in volume Bragg gratings, including, but not limited to, volume Bragg gratings for holography applications. Several structures are di...
|
|
WO/2022/100487A1 |
Disclosed is an amino-combretastatin derivative, and in particular a compound represented by general formula (I), a pharmaceutically acceptable salt thereof, a hydrate thereof, or a hydrate of the pharmaceutically acceptable salt thereof...
|
|
WO/2022/104383A1 |
Provided are compounds useful for treating, preventing, reducing the occurrence of, slowing the progression of, or reducing, ameliorating, or alleviating the symptoms associated with a condition selected from the group consisting of: pre...
|
|
WO/2022/091065A1 |
In a cocrystal, a pharmaceutical composition comprising same, and a preparation method therefor, of the present invention, a novel cocrystal comprises niclosamide and nafamostat, or a pharmaceutically acceptable salt thereof. The novel c...
|
|
WO/2022/092260A1 |
The present invention addresses the problem of providing a cross-coupling reaction method that can use a wide variety of compounds as starting materials, that can substantially not use organic solvent, and that can rapidly provide reacti...
|
|
WO/2022/088302A1 |
The present invention relates to the technical field of organic synthesis of tire rubber, in particular, to a preparation method for isophthalamide. The isophthalamide is prepared by using m-phthalodinitrile as a reaction raw material, a...
|
|
WO/2022/084046A1 |
The present invention relates to a process for preparing methyl methacrylate (MMA) and/or methacrylic acid (MAS) with improved yield, comprising the process steps of amidation, conversion and hydrolysis/esterification, especially high yi...
|
|
WO/2022/082752A1 |
A DMF recycling method. The method comprises: a neutralization step: adding an alkaline neutralizer into a DMF stock solution, controlling the pH value of the mixed solution to be within a preset range, and carrying out a neutralization ...
|
|
WO/2022/083494A1 |
The present application relates to a cis-para-substituted cyclohexylaminonitrile salt represented by formula (I), a preparation method therefor and use thereof as an intermediate for preparing a pesticide, and a method for preparing the ...
|
|
WO/2022/079574A1 |
The present disclosure provides compositions and methods for reducing inflammation to improve or maintain mental health or physical health in an individual. In some aspects, the compositions include at least one 5HT2A agonist and at leas...
|
|
WO/2022/075396A1 |
[Problem] The purpose of the present invention is to provide a compound which is suitable for a low refractive index layer in a capping layer in order to improve the light extraction efficiency of an organic EL element. [Solution] The pr...
|
|
WO/2022/072401A1 |
Provided herein are small molecule inhibitors of coronavirus attachment and entry, related pharmaceutical compositions, uses, and methods thereof, wherein the compound has a structure of Formula (I):
|
|
WO/2022/071363A1 |
Provided is a new production method for a fluorinated organic compound (1) which involves a step A in which, in a liquid composition containing an organic solvent, IF5 is used to fluorinate a hydrogen atom-containing organic compound (2)...
|
|
WO/2022/073003A1 |
The present application provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein Y, R1, R2, R3 and R4 are described herein. The methods of using these compounds to inhibit tetramerization of PF4 and to tr...
|
|
WO/2022/063350A1 |
The subject of the present invention is a lipidoid of general formula (I), wherein X, Y, Z and R are as defined in the claims. This lipidoid is useful as a transfection agent. The invention further describes transfection agents, transfec...
|
|
WO/2022/064454A1 |
The present invention discloses a process for the synthesis of compound of formula (VII) or a salt thereof, wherein, R, R1, R2, R3, R4a and R4b are as defined in the detailed description. The process further comprises the synthesis of an...
|
|
WO/2022/053541A1 |
The present invention relates to new compounds having appetite-suppressing effects and their uses as a drug for treating diseases and disorders, especially metabolite syndrome.
|
|
WO/2022/053804A1 |
The present invention relates to a composite form of tetraacetylethylenediamine (TAED) and a method for its preparation. The composite form may comprise a new crystalline form. The invention also relates to the crystalline form itself. T...
|
